SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

BRISBANE, Calif.--(BUSINESS WIRE)--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.

Sandy Macrae, Sangamo’s President and Chief Executive Officer is scheduled to present on Wednesday, September 27th at 11:00AM ET. A live webcast of the presentation will be available and on the Company’s Investor Events A replay of the presentation will be available on the Sangamo Therapeutics website for 90 days after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit and connect with us on and .

EN
20/09/2023

Underlying

SGMOSangamo Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sangamo Therapeutics Inc.

 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR ...

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval ...

February 3, 2026 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten O...

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined offering price o...

February 3, 2026 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA f...

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene civaparvovec continues to show favorable safety and tolerability profile Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026...

December 18, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-5...

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new the...

December 2, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submissio...

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo’s meeting with the FDA...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch